Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 27

Results For "IRA"

1454 News Found

Apollo Hospitals hosts specialist dialogue on vertigo diagnosis challenges
Hospitals | April 04, 2026

Apollo Hospitals hosts specialist dialogue on vertigo diagnosis challenges

Hands-on clinical workshop in Bengaluru brings together neurologists, ENT specialists and physicians


India’s bioeconomy hits $165.7 billion as govt unveils fresh biopharma push
Biotech | April 03, 2026

India’s bioeconomy hits $165.7 billion as govt unveils fresh biopharma push

DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports


Biocon Foundation, BeST Cluster and NCBS launch first BioWISE Cohort for postgraduate women students
Biotech | April 03, 2026

Biocon Foundation, BeST Cluster and NCBS launch first BioWISE Cohort for postgraduate women students

Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship


Marksans Pharma receives USFDA approval for Benzonatate capsules
Drug Approval | April 02, 2026

Marksans Pharma receives USFDA approval for Benzonatate capsules

Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract


Molbio’s digital radiology arm secures CE MDR certification for its medical imaging portfolio
Medical Device | April 02, 2026

Molbio’s digital radiology arm secures CE MDR certification for its medical imaging portfolio

Certification by TÜV SÜD Product Service GmbH reinforces the company's commitment to globally benchmarked standards in safety, quality, and performance


D2C nutrition brand BeastLife raises Rs 20 crore at Rs 320 crore valuation from GVFL and Equentis
News | April 02, 2026

D2C nutrition brand BeastLife raises Rs 20 crore at Rs 320 crore valuation from GVFL and Equentis

The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years


Biogen bags FDA nod for high dose SPINRAZA in spinal muscular atrophy
Drug Approval | April 02, 2026

Biogen bags FDA nod for high dose SPINRAZA in spinal muscular atrophy

The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases


Torqur taps Lonza to power late-stage push for skin cancer therapy
Biotech | April 01, 2026

Torqur taps Lonza to power late-stage push for skin cancer therapy

Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds


Roche launches groundbreaking multiplex test to boost blood safety
News | March 31, 2026

Roche launches groundbreaking multiplex test to boost blood safety

The new assay consolidates screening for four major viral threats into a single workflow


Lupin receives FDA’s tentative approval for Sugammadex injection
Drug Approval | March 31, 2026

Lupin receives FDA’s tentative approval for Sugammadex injection

Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery